Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genzyme | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Genzyme

1Q results weighed down by Allston troubles.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme 1Q10

1Q Revenues: $1.1 billion (-7%)

1Q Loss: $115 million (earnings of $196 million in 1Q09)

Comments: Revenues were impacted by the shutdown of the Allston manufacturing facility. Cerezyme sales were down 40% to $179 million. Fabrazyme sales dropped from $122 million to $53 million. Myozyme sales were up 28% to $86 million. For more on the company’s consent decreee with the FDA , see this story.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters